TRIPLE NEGATIVE WO39391

Study #WO39391

A Phase III, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple‑Negative Breast Cancer

Back To Clinical Trials